{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:47:38Z","timestamp":1767682058828,"version":"3.48.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["20232BAB216039"],"award-info":[{"award-number":["20232BAB216039"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023ZD0506200"],"award-info":[{"award-number":["2023ZD0506200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-COVID-19 pulmonary fibrosis (PCPF) is one of the most common diagnoses after COVID-19 acute infection. However, the interventions for long-term prognosis of PCPF are relatively lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>We aimed to observe one-year readmission and mortality rates among patients with PCPF, and tried to explore the impact of small-molecule antiviral drugs (SMADs) during hospitalization on the prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A total of 372 patients diagnosed as PCPF were enrolled. 293 of them treated with SMADs and the remaining 79 treated with NO SMADs. One-year readmission and mortality rates were evaluated via regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During hospitalization, 16 of the 372 patients died. An additional 19 survivors died within one-year postdischarge. Among survivors, 49.62% were readmitted. Compared to the NO-SMAD group, the SMAD group presented a lower one-year readmission rate (45.97%vs. 63.64%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.020) and a reduced risk of one-year readmission (HR\u202f=\u202f0.65, 95% CI: 0.44 to 0.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.030).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nearly half of PCPF patients experienced readmission within one-year following their initial hospitalization for acute COVID-19. Importantly, treatment with SMADs during the acute infection phase was significantly associated with a reduced readmission rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2025.1733465","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:41:32Z","timestamp":1767681692000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect and safety of small-molecule antiviral drugs on long prognosis of post-COVID-19 pulmonary fibrosis: a real-world study in China"],"prefix":"10.3389","volume":"16","author":[{"given":"Yilin","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Den","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dechang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tieying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3390\/jcm10112452","article-title":"Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic","volume":"10","author":"Ambardar","year":"2021","journal-title":"J. Clin. Med."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/diagnostics14060621","article-title":"Short- and long-term chest-CT findings after recovery from COVID-19: a systematic review and meta-analysis","volume":"14","author":"Babar","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.3390\/ijms22147498","article-title":"Extension of collagen deposition in COVID-19 post mortem lung samples and computed tomography analysis findings","volume":"22","author":"Ball","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e230535","DOI":"10.1148\/radiol.230535","article-title":"Chest CT lung abnormalities 1 year after COVID-19: a systematic review and Meta-analysis","volume":"308","author":"Bocchino","year":"2023","journal-title":"Radiology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"103813","DOI":"10.1016\/j.resp.2021.103813","article-title":"Potential benefits of precise corticosteroid therapy for critical COVID-19","volume":"297","author":"Chen","year":"2022","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/s2213-2600(20)30225-3","article-title":"Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e3001687","DOI":"10.1371\/journal.pbio.3001687","article-title":"Why does viral RNA sometimes persist after recovery from acute infections?","volume":"20","author":"Griffin","year":"2022","journal-title":"PLoS Biol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s0140-6736(21)01755-4","article-title":"1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study","volume":"398","author":"Huang","year":"2021","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.medcli.2022.12.021","article-title":"Comparison of two antifibrotic treatments for lung fibrosis in post-COVID-19 syndrome: a randomized, prospective study","volume":"160","author":"Kerget","year":"2023","journal-title":"Med. Clin."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12931-023-02496-1","article-title":"Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19","volume":"24","author":"Kooistra","year":"2023","journal-title":"Respir. Res."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1080\/07853890.2022.2039954","article-title":"COVID-19-related end stage lung disease: two distinct phenotypes","volume":"54","author":"Kostopanagiotou","year":"2022","journal-title":"Ann. Med."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e222600","DOI":"10.1148\/radiol.222600","article-title":"An integrated radiologic-pathologic understanding of COVID-19 pneumonia","volume":"306","author":"Lee","year":"2023","journal-title":"Radiology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1513\/AnnalsATS.202008-1002OC","article-title":"Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment","volume":"18","author":"Myall","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.5858\/arpa.2021-0519-SA","article-title":"Late complications of COVID-19","volume":"146","author":"Roden","year":"2022","journal-title":"Arch. Pathol. Lab Med."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"107362","DOI":"10.1016\/j.rmed.2023.107362","article-title":"Prolonged-release pirfenidone in patients with pulmonary fibrosis as a phenotype of post-acute sequelae of COVID-19 pneumonia. Safety and efficacy","volume":"217","author":"Sansores","year":"2023","journal-title":"Respir. Med."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"E383","DOI":"10.1148\/radiol.2021211396","article-title":"CT of post-acute lung complications of COVID-19","volume":"301","author":"Solomon","year":"2021","journal-title":"Radiology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/17476348.2021.1916472","article-title":"Pulmonary fibrosis secondary to COVID-19: a narrative review","volume":"15","author":"Tanni","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of Treatment with Nirmatrelvir and the risk of post-COVID-19 condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"EVIDoa2300046","DOI":"10.1056\/evidoa2300046","article-title":"Long-term dysfunction of taste papillae in SARS-CoV-2","volume":"2","author":"Yao","year":"2023","journal-title":"NEJM Evid."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/s1473-3099(24)00171-3","article-title":"The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China","volume":"24","author":"Zuo","year":"2024","journal-title":"Lancet Infect. Dis."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1733465\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:41:38Z","timestamp":1767681698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1733465\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":21,"alternative-id":["10.3389\/fmicb.2025.1733465"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1733465","relation":{},"ISSN":["1664-302X"],"issn-type":[{"type":"electronic","value":"1664-302X"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1733465"}}